End-of-day quote
OTC Markets
06:00:00 2024-05-29 pm EDT
|
5-day change
|
1st Jan Change
|
0.000001
USD
|
-.--%
|
|
-.--%
|
-99.96%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
102.9
|
67.1
|
54.75
|
136.1
|
200.3
|
49.59
|
Enterprise Value (EV)
1 |
51.34
|
8.512
|
44.24
|
154.4
|
170.6
|
60.62
|
P/E ratio
|
-2.45
x
|
-5.81
x
|
-1.16
x
|
-3.13
x
|
-4.25
x
|
-1.11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.2
x
|
3.03
x
|
18
x
|
79.2
x
|
108
x
|
19.1
x
|
EV / Revenue
|
8.56
x
|
0.38
x
|
14.5
x
|
89.8
x
|
91.8
x
|
23.4
x
|
EV / EBITDA
|
-1.48
x
|
-0.73
x
|
-0.97
x
|
-4.06
x
|
-3.83
x
|
-1.37
x
|
EV / FCF
|
-2.12
x
|
-3.87
x
|
-1.5
x
|
-6.69
x
|
-7.56
x
|
-2.47
x
|
FCF Yield
|
-47.2%
|
-25.9%
|
-66.5%
|
-14.9%
|
-13.2%
|
-40.6%
|
Price to Book
|
2.16
x
|
1.28
x
|
7.09
x
|
-5.93
x
|
9.3
x
|
-2.6
x
|
Nbr of stocks (in thousands)
|
50,711
|
56,867
|
57,029
|
64,207
|
89,015
|
89,346
|
Reference price
2 |
2.030
|
1.180
|
0.9600
|
2.120
|
2.250
|
0.5550
|
Announcement Date
|
3/15/18
|
3/14/19
|
3/3/20
|
3/16/21
|
3/29/22
|
3/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
6
|
22.15
|
3.049
|
1.719
|
1.858
|
2.593
|
EBITDA
1 |
-34.73
|
-11.74
|
-45.44
|
-38.01
|
-44.6
|
-44.39
|
EBIT
1 |
-36.44
|
-11.93
|
-45.66
|
-38.5
|
-45.08
|
-44.84
|
Operating Margin
|
-607.42%
|
-53.87%
|
-1,497.67%
|
-2,239.5%
|
-2,426.43%
|
-1,729.43%
|
Earnings before Tax (EBT)
1 |
-42.55
|
-11.25
|
-47.11
|
-40.49
|
-45.26
|
-44.37
|
Net income
1 |
-41.83
|
-11.25
|
-47.06
|
-40.49
|
-45.26
|
-44.37
|
Net margin
|
-697.17%
|
-50.81%
|
-1,543.36%
|
-2,355.56%
|
-2,436.06%
|
-1,711.11%
|
EPS
2 |
-0.8273
|
-0.2031
|
-0.8258
|
-0.6765
|
-0.5300
|
-0.5000
|
Free Cash Flow
1 |
-24.21
|
-2.202
|
-29.43
|
-23.07
|
-22.58
|
-24.59
|
FCF margin
|
-403.57%
|
-9.94%
|
-965.16%
|
-1,342.34%
|
-1,215.36%
|
-948.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/18
|
3/14/19
|
3/3/20
|
3/16/21
|
3/29/22
|
3/28/23
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
1 |
0.467
|
0.512
|
0.428
|
0.451
|
0.652
|
0.686
|
0.712
|
0.543
|
0.731
|
EBITDA
|
-11.46
|
-11.13
|
-10.63
|
-11.38
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.58
|
-11.25
|
-10.75
|
-11.5
|
-12.41
|
-12.02
|
-10.88
|
-9.538
|
-11.51
|
Operating Margin
|
-2,480.09%
|
-2,197.46%
|
-2,511.68%
|
-2,549.89%
|
-1,902.91%
|
-1,751.9%
|
-1,528.23%
|
-1,756.54%
|
-1,574.15%
|
Earnings before Tax (EBT)
1 |
-11.63
|
-11.27
|
-10.71
|
-11.65
|
-12.44
|
-11.99
|
-10.72
|
-9.23
|
-11.04
|
Net income
1 |
-11.63
|
-11.27
|
-10.71
|
-11.65
|
-12.44
|
-11.99
|
-10.72
|
-9.23
|
-11.04
|
Net margin
|
-2,490.15%
|
-2,200.98%
|
-2,503.04%
|
-2,583.37%
|
-1,907.36%
|
-1,747.23%
|
-1,505.2%
|
-1,699.82%
|
-1,510.94%
|
EPS
2 |
-0.1500
|
-0.1300
|
-0.1200
|
-0.1300
|
-0.1400
|
-0.1300
|
-0.1200
|
-0.1100
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/13/21
|
7/27/21
|
11/2/21
|
3/29/22
|
5/3/22
|
8/9/22
|
11/14/22
|
3/28/23
|
5/9/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
18.2
|
-
|
11
|
Net Cash position
1 |
51.6
|
58.6
|
10.5
|
-
|
29.7
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.48
x
|
-
|
-0.2486
x
|
Free Cash Flow
1 |
-24.2
|
-2.2
|
-29.4
|
-23.1
|
-22.6
|
-24.6
|
ROE (net income / shareholders' equity)
|
-64.3%
|
-22.5%
|
-156%
|
531%
|
6,384%
|
-3,521%
|
ROA (Net income/ Total Assets)
|
-24.6%
|
-12.5%
|
-52.3%
|
-54.5%
|
-45.4%
|
-44.2%
|
Assets
1 |
169.9
|
90.23
|
90.05
|
74.33
|
99.68
|
100.5
|
Book Value Per Share
2 |
0.9400
|
0.9200
|
0.1400
|
-0.3600
|
0.2400
|
-0.2100
|
Cash Flow per Share
2 |
0.6800
|
0.8500
|
0.3900
|
0.4400
|
0.9100
|
0.4300
|
Capex
1 |
0.04
|
-
|
2.33
|
0.04
|
0.01
|
0.02
|
Capex / Sales
|
0.72%
|
-
|
76.32%
|
2.5%
|
0.59%
|
0.66%
|
Announcement Date
|
3/15/18
|
3/14/19
|
3/3/20
|
3/16/21
|
3/29/22
|
3/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -99.96% | 90 | | +46.19% | 56.65B | | -6.14% | 39.44B | | +39.19% | 39.03B | | -6.65% | 26.86B | | +12.33% | 26.75B | | -21.78% | 19.03B | | -0.35% | 12.28B | | +24.18% | 12.26B | | +28.38% | 12.04B |
Other Biotechnology & Medical Research
|